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We evaluated the clinical usefulness of spoligotyping,
a polymerase chain reaction–based method for simultane-
ous detection and typing of Mycobacterium tuberculosis
strains, with acid-fast bacilli–positive slides from clinical
specimens or mycobacterial cultures. Overall sensitivity
and specificity were 97% and 95% for the detection of M.
tuberculosis and 98% and 96% when used with clinical
specimens. Laboratory turnaround time of spoligotyping
was less than that for culture identification by a median of
20 days. In comparison with IS6110-based restriction frag-
ment length polymorphism typing, spoligotyping overesti-
mated the number of isolates with identical DNA
fingerprints by ≈50%, but showed a 100% negative predic-
tive value. Spoligotyping resulted in the modification of
ongoing antimycobacterial treatment in 40 cases and
appropriate therapy in the absence of cultures in 11 cases.
The rapidity of this method in detection and typing could
make it useful in the management of tuberculosis in a clin-
ical setting. 
T
he last decade has seen a dramatic resurgence in the
incidence of tuberculosis throughout the world and an
increased need for more rapid methods to diagnose and pre-
vent dissemination of this disease (1). Well-equipped clini-
cal laboratories can detect tuberculosis cases within 14 to
21 days by using liquid culturing systems such as BACTEC
(Becton Dickinson, Sparks, MD, USA). Moreover, several
studies have verified the usefulness of nucleic acid amplifi-
cation–based methods for diagnosis of Mycobacterium
tuberculosis infections in <24 hours (2–4). Concomitantly,
recently characterized molecular markers for typing
mycobacterial strains have greatly facilitated and improved
the study of tuberculosis epidemiology (5–8).
Restriction fragment length polymorphism (RFLP) typ-
ing with insertion element IS6110 as a probe has become
the most widely used method for differentiating strains of
M. tuberculosis isolates (7,8). However, because the appli-
cation of RFLP typing is restricted to mycobacterial cul-
tures, 20–40 days are required before sufficient
mycobacteria are available to obtain sufficient DNAneeded
for this method. This time restriction limits the usefulness of
RFLP typing, especially in studying possible nosocomial
transmission of tuberculosis in a clinical setting.
Spoligotyping, a new method for simultaneous detec-
tion and typing of M. tuberculosis complex bacteria, has
been recently developed (9–11). This method is based on
polymerase chain reaction (PCR) amplification of a highly
polymorphic direct repeat locus in the M. tuberculosis
genome. Results can be obtained from a M. tuberculosis
culture within 1 day. Thus, the clinical usefulness of
spoligotyping is determined by its rapidity, both in detect-
ing causative bacteria and in providing epidemiologic
information on strain identities. Implementing such a
method in clinic settings would be useful in surveillance of
tuberculosis transmission and in interventions to prevent
further spread of this disease. 
The aims of this study were to evaluate 1) the reliabili-
ty of spoligotyping when used with clinical specimens, 2)
the potential usefulness of the method in distinguishing M.
tuberculosis from other nontuberculous mycobacteria (pri-
marily  M. avium), and 3) the feasibility and impact of
spoligotyping in managing tuberculosis in clinical settings. 
Patients and Methods
Specimen Collection 
We conducted a 2-year survey of suspected cases of
tuberculosis with spoligotyping of acid-fast bacilli
(AFB)–positive specimens collected consecutively from
January 2000 to December 2001 in the Microbiology
Laboratory at L. Sacco Hospital in Milan. Three types of
specimens were included. The first was material scraped
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ical specimens, which were obtained from patients admit-
ted to the hospital. These clinical specimens included
sputum, bronchoalveolar lavage, bone marrow aspirate,
feces, cerebrospinal fluid, and urine. The second was sam-
ples obtained from liquid culture medium containing
growing mycobacteria (BACTEC, Becton Dickinson). The
third was a mycobacterial colony grown on solid medium
(Lowenstein-Jensen). The hospital microbiology laborato-
ry conducted isolation (both in solid and liquid media),
identification, and antimicrobial susceptibility testing by
using standard methods (12) on all specimens. The results
of spoligotyping were immediately provided to the physi-
cians treating the patients.
Clinical Characteristics 
Demographic and epidemiologic data were obtained
from the medical records of all patients with AFB-positive
specimens, including medical history of mycobacteriosis,
HIV status, dates and results of mycobacterial smears,
signs, symptoms, radiographs of patients with tuberculo-
sis, and CD4+ cell counts (for HIV-infected patients). Data
regarding the response time of the method used, possible
variation in treatments following spoligotyping results,
and patient clinical responses were also obtained.
Isolation of DNA
DNA was isolated from AFB-positive slides as previ-
ously described (13). Briefly, stained microscopic prepara-
tions were washed in xylol and absolute ethanol, scraped
with a sterile blade, and collected in a microcentrifuge tube
in 1 × phosphate buffer. The samples were centrifuged for
10 min at 13,000 rpm. The pellets were resuspended in 100
µL lysis buffer (10 mmol/L Tris-HCl, 50 mmol/L KCl, 2.5
mmol/L MgCl2, 0.45% Tween 20, 0.45% Nonidet P40, and
10 mg/mL proteinase K) and incubated for 3 h at 56°C or
overnight at 37°C. The samples were then incubated for 15
min at 95°C and centrifuged for 15 min at 13,000 rpm, and
the supernatants were transferred to a new microcentrifuge
tube and used in PCR. Mycobacteria were grown in culture,
and their DNA was isolated as previously described (6).
RFLP Fingerprinting Analysis and Spoligotyping 
Isolates of M. tuberculosis were genotyped by RFLP
using the IS6110 probe as a genetic marker, as previously
described by van Embden et al. (6). Spoligotyping was
performed on genomic DNAby using the standard method
described by Kamerbeek et al. (9). Control samples were
used in these procedures as previously described (14).
Computer-assisted Analysis of Typing Patterns 
Gel Compar software version 4.1 (Applied Maths,
Kortrijk, Belgium) was used to compare the hybridization
patterns obtained by spoligotyping and RFLP fingerprint-
ing. The software clustered strains with the same genotyp-
ic pattern and defined similarity dendrograms joining the
obtained clusters. The results of the analysis were com-
pared with our database containing all DNA patterns
derived from tuberculosis cases analyzed (the database
contains RFLP data from >4,500 different isolates in our
region). 
Statistical Analysis 
The sensitivity and specificity of spoligotyping in dis-
tinguishing  M. tuberculosis from nontuberculous
mycobacteria were calculated in comparison with culture
results that excluded analysis of patients without culture
confirmation. The sensitivity and specificity of spoligotyp-
ing in typing M. tuberculosis isolates were calculated in
comparison with IS6110 clustering. 
Results
Patient Characteristics 
Three hundred fifty AFB-positive slides from 164
episodes of suspected mycobacteriosis in 148 patients
were analyzed. One hundred seven slides were obtained
from fresh material: sputum (n = 65), stool (n = 19), lymph
node aspirate (n = 12), bronchoaspirate (n = 4), urine (n =
3), skin biopsy (n = 2), biliar liquid (n =1), and pericardial
fluid (n = 1). One hundred five samples were obtained
after growth of mycobacteria from liquid medium, and 138
samples derived from culture of different materials (main-
ly blood, but also sputum, bone marrow aspirate, cerebral
spinal fluid, and others) were obtained after growth on
solid medium. The characteristics of the 148 patients are
shown in Table 1.
Sensitivity and Specificity of 
Spoligotyping versus Culture 
Culture confirmation was obtained in 317 (90.6%) of
350 AFB-positive slides from 138 of 164 episodes of sus-
pected mycobacteriosis (Table 2). M. tuberculosis was
isolated from 188 specimens from 77 patient episodes.
Among these, isoniazid resistance was detected in 12
patients (15.6%), rifampin resistance in 11 patients
(14.3%), streptomycin resistance in 4 patients (5.2%), and
ethambutol resistance in 2 patients (2.6%). We also
observed 6 patients with multidrug-resistant tuberculosis
(resistance to at least isoniazid and rifampin). Fifty-six
patients (72.7%) were infected with a strain susceptible to
all 4 drugs.
One hundred ninety-eight of 350 AFB slides showed
positive results by spoligotyping. Culture results con-
firmed the diagnosis of tuberculosis according to spoligo-
typing positivity in 182 (96.8%) of these 198 specimens.
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cultures from 10 patients. The PCR products obtained
from 6 specimens of nontuberculous mycobacteria (2 M.
xenopi, 2 M. fortuitum, and 2 M. avium) hybridized with
M. tuberculosis–specific oligonucleotides, which indicated
that that false-positive spoligotyping results were possible.
However, mixed infections with 2 different mycobacteria
cannot be ruled out. 
The spoligotyping response was negative in specimens
from 152 patients: 23 specimens showed no growth in cul-
ture, 123 were nontuberculous mycobacteria, and 6
showed growth characteristic of M. tuberculosis (Table 2).
Three of these 6 false-negative spoligotyping results were
from slides with very high concentrations of AFB, and a
positive result was obtained when we repeated the test at a
higher dilution (1:10). 
In comparison with culture results, the sensitivity of
spoligotyping was 98% for clinical specimens, 91% for
slides obtained from liquid medium, and 100% for slides
obtained directly from a mycobacterial colony on
Lowenstein-Jensen solid medium. The corresponding
specificities were 96% (clinical specimens), 98% (liquid
medium), and 94% (solid medium), respectively (Table 2).
Clinical Application of Spoligotyping 
Under optimal conditions, spoligotyping requires <24
hours for results. However, in the present study, response
time was evaluated, taking into consideration routine pro-
cessing time in the laboratory. The time from receipt of
clinical specimens to obtaining spoligotyping results was
1–26 days (median 6 days). However, spoligotyping
results from clinical specimens were obtained a median of
20 days (mean ± SD, 22.9 ± 18.6) sooner than those
obtained by culture confirmation of tuberculosis and a
median of 29 days (35.0 ± 25.2) sooner than those obtained
by susceptibility testing. In contrast, RFLP typing results
were obtained after a median of 75 days (range 24–160)
(Table 3).
The use spoligotyping in determining treatment for 164
episodes of suspected mycobacteriosis was evaluated
(Figure 1). In 25 episodes, patients did not begin antimy-
cobacterial treatment because clinicians judged the AFB
results to be not suggestive of true mycobacteriosis; none
of these patients had clinical and radiologic features of
tuberculosis (virtually all of these were infections with M.
gordonae and M. xenopi isolates). Four patients died with-
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antimycobacterial drug. 
Clinicians waited until spoligotyping results were
obtained before choosing the appropriate therapy for 31
other patients. Subsequently, 20 patients began standard
antituberculosis regimens (isoniazid, rifampin, pyrazi-
namide, and/or ethambutol), whereas the 11 other patients
began treatment for infection with M. avium (clar-
ithromycin, ethambutol, rifabutin, and/or ciprofloxacin).
In all cases, the choice of the treatment based on spoligo-
typing was not changed after culture and susceptibility test
results were obtained.
Empiric antimycobacterial therapy was given to the
remaining 104 patients before spoligotyping results were
obtained. Seventy-six of these patients received antituber-
culosis treatment against M. tuberculosis infections, and
28 received therapy for infection with M. avium based on
clinical presentation. Therapy was subsequently modified
as a result of the spoligotyping results in 14 of these 104
patients. In 5 patients in whom spoligotyping results were
negative and subsequent cultures showed nontuberculous
mycobacteria, antituberculosis treatment was replaced
with treatment for infection with M. avium. In contrast, in
8 patients in whom spoligotyping results were positive and
subsequent cultures were positive for M. tuberculosis,
treatment for infection with M. avium was replaced by
antituberculosis treatment. In 1 patient, the homology of
the spoligotyping pattern with patterns of other patients
included in our data bank demonstrated that the isolate
originated from an outbreak caused by multidrug-resistant
strains. Consequently, therapy was modified to include
second-line antituberculosis drugs, which previous in vitro
susceptibility data had shown were active against the spe-
cific strains. Subsequent in vitro susceptibility data con-
firmed the spoligotyping results. False-positive
spoligotyping results in 9 patients did not result in errors in
prescribing treatment. These patients continued ongoing
treatment, primarily on the basis of previous spoligotyping
results or because of a positive response to treatment.
Analysis of Different Isolates from the Same Patient 
We analyzed 34 spoligotyping-positive specimens from
6 patients with successive episodes of culture-confirmed
tuberculosis (≥3 months apart). In these patients, spoligo-
typing was modified to distinguish relapses from new
infections. After the samples were decoded, all episodes
were classified as true relapses, and no new infections
were detected. The banding patterns of the successive
specimens matched those of their corresponding initial iso-
lates. The subsequent RFLP results confirmed those
obtained with spoligotyping.
Genotyping 
The reproducibility of spoligotyping was demonstrated
by the identity of results obtained with clinical samples
and corresponding cultures from different anatomic sites in
the same episode (18 patients), and from episodes of recur-
rent tuberculosis in the same person (5 patients). Thirty-
nine distinct spoligotyping patterns were observed; 55% of
the specimens were grouped into 10 clusters, and the oth-
ers had unique spoligotypes. Sixty-one different RFLPpat-
terns were seen in 64 isolates. Of these 61 patterns, 3 were
shared by 2 isolates, while the remaining 58 patterns
(95%) were observed in only 1 isolate. 
One of the 3 clusters identified by RFLP was a false
cluster because it showed a 1-band pattern that correctly
matched 2 different spoligotypes. In the remaining 2 RFLP
clusters, complete concordance with spoligotyping was
observed. The remaining 8 clusters detected by spoligotyp-
ing were not confirmed by RFLP analysis. Therefore,
although it demonstrated 100% sensitivity, spoligotyping
overestimated the number of clustered isolates by ≈50%
(specificity 47.5%). Conversely, RFLP analysis had 100%
specificity, but lower sensitivity. However, most of the iso-
lates classified as clustered by spoligotyping but not by
RFLP showed  >50% similarity in their IS6110 patterns
(Figure 2). Using spoligotyping of clinical samples
without culture confirmation, we were able to diagnose an
Spoligotyping Mycobacterium tuberculosis
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Figure 1. Clinical and therapeutic implications of spoligotyping
results in treating suspected mycobacterial diseases. AFB, acid-
fast bacilli; pts, patients; MAC, Mycobacterium avium complex; TB,
tuberculosis. *Twenty-five patients did not begin treatment
because they did not have clinical and radiologic features of tuber-
culosis. Four patients died within a few days after admission with-
out receiving any antimycobacterial drug.M. bovis infection and rapidly identify 2 cases of recurrent
tuberculosis in patients with the same spoligotyping pat-
tern in both followup specimens and the initial M. tubercu-
losis strain isolated several months earlier. 
Discussion
Recent characterization of biologic markers for typing
M. tuberculosis strains has greatly facilitated and improved
tuberculosis epidemiology. IS6110 RFLP typing is the
most widely used method for differentiating M. tuberculo-
sis strains (15–19). However, RFLP analysis requires
growth of mycobacterial colonies, which involves a con-
sistent lag time between epidemiologic events and typing
results. Thus, time remains a limiting factor in obtaining a
highly effective method for epidemiologic surveys and
preventing the spread of disease.
The development of new PCR-based typing methods
(4,5,9,10,20–23) has allowed rapid mycobacterial identifi-
cation to be combined with epidemiologic typing results.
Thus, molecular epidemiologic information can be com-
bined in the context of epidemic events and tuberculosis
transmission. Spoligotyping appears to have the specific
characteristics needed to satisfy these issues of epidemics
and tuberculosis transmission (24–28). This method per-
mits the concomitant identification and differentiation of
M. tuberculosis strains and avoids the timing problems
associated with the slow growth of these bacteria (10,11).
However, although spoligotyping can be used with clinical
specimens (9), the usefulness of any PCR-based typing
method in the clinical setting has yet to be demonstrated.
In addition, although previous studies have investigated
the effect of specific methodologic issues on the perform-
ance of several typing techniques (20–22,24–30), we have
demonstrated the usefulness of a PCR–based technique in
the clinical setting for diagnostic purposes, as well as for
epidemiologic studies of tuberculosis transmission.
We have also shown that spoligotyping can be satisfac-
torily used with clinical samples. The performance of
spoligotyping was satisfactory with all clinical specimens
used, and its specificity and sensitivity were 98% and 96%,
respectively. These features are comparable with those of
commercial PCR methods used for detecting M. tuberculo-
sis from clinical samples (19). Moreover, the opportunity
to combine rapid diagnostic information and molecular
epidemiologic data represents an important advance in the
epidemiologic control of tuberculosis. 
Several molecular typing studies have compared differ-
ent methods for M. tuberculosis typing. IS6110-based
RFLPhas been found to be more discriminative than direct
repeat–based spoligotyping (20–31). Although our data
confirm that spoligotyping vastly overestimates the num-
ber of clustered isolates, this method has a lower discrimi-
natory power than IS6110-RFLP. However, spoligotyping
also has a higher negative predictive value, thus enabling
the clinician to exclude a particular clustered strain as a
cause of infection, if known drug-resistant variants are
present. 
This study showed that spoligotyping can provide use-
ful data to clinicians in different settings. Although co-
infection with M. tuberculosis and nontuberculous
mycobacteria cannot be ruled out, the ability to differenti-
ate between M. tuberculosis and other mycobacteria was
demonstrated in 27% of the patients. Some patients began
therapy after evaluation of spoligotyping results, while
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Figure 2. Spoligotype dendrograms gener-
ated by clustered Mycobacterium tuberculo-
sis strains after computer analysis
compared with the corresponding dendro-
grams of IS6110 DNA fingerprints.others changed treatments because spoligotyping did not
confirm the initial diagnosis. Time of response for spolig-
otyping was shorter than that of culture confirmation of
tuberculosis by a median of 20 days and that of suscepti-
bility results by a median of 29 days. In addition, a medi-
an of 6 days was needed for obtaining spoligotyping
results, compared with 75 days for RFLP typing results.
Comparison of molecular typing patterns identified 6
patients with reactivation of tuberculosis caused by the
same strain of M. tuberculosis, a finding that can differen-
tiate between relapse and new infection in a new episode
of tuberculosis. In 1 patient, we found that the spoligotyp-
ing pattern was identical to that of other strains that
belonged to a cluster of multidrug-resistant tuberculosis.
This observation resulted in the modification of antituber-
culosis treatment 34 days before susceptibility data were
available. Moreover, information obtained by spoligotyp-
ing was relevant and useful in therapeutic management of
≈33% of the patients.
The clinical utility of spoligotyping may not be fully
apparent by analyzing the results of this study, primarily
because of the lack of clustered episodes of tuberculosis
during the study period. However, spoligotyping would
have been useful during a period or in a setting character-
ized by the emergence of M. tuberculosis outbreaks
(8,32,33). We have also shown that the usefulness of
spoligotyping is increased when results are compared with
data on other tuberculosis patients and a DNA database on
M. tuberculosis strains.
In conclusion, this study underscores the need to imple-
ment rapid molecular epidemiologic methods in managing
tuberculosis epidemics. We have shown that spoligotyping
is a useful method for screening and epidemiologic control
of tuberculosis dissemination, particularly when results are
required quickly, such as in outbreaks, or in the manage-
ment of transmission of multidrug-resistant tuberculosis,
especially in restricted high-risk situations such as prisons,
schools, and hospitals.
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